Suppr超能文献

β受体阻滞剂汇总项目(BBPP):心肌梗死后患者随机试验的亚组研究结果。β受体阻滞剂汇总项目研究组。

The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The Beta-Blocker Pooling Project Research Group.

出版信息

Eur Heart J. 1988 Jan;9(1):8-16.

PMID:2894312
Abstract

The objective of the Beta-Blocker Pooling Project (BBPP) was to collect and analyse data from the major long-term secondary prevention trials in order to determine whether there are subsets of post-infarction patients who benefit to a greater or lesser extent from beta-blocker therapy than the average patient population. One-year all-cause mortality data from nine trials involving 13,679 patients were obtained. Overall, mortality was 24% lower in the beta-blocker group compared to the placebo group. However, there was heterogeneity among the results of the trials, which tested seven different beta-blockers. Subgroups with high placebo group mortality (e.g. patients with a history of previous myocardial infarction (MI), angina pectoris, mechanical or electrical complications, and digitalis usage) seemed to benefit particularly from beta-blocker treatment. These findings were consistent in the nine trials. Patients in the lower risk subgroups also appeared to benefit from beta-blockers, but this benefit was smaller in absolute terms and inconsistent across the trials. There was no evidence that treatment outcome was related to gender, baseline level of heart rate or blood pressure, or time of initiation of treatment after hospital admission. In conclusion, the Pooling Project indicates that high risk MI patients, without contraindications to beta-blockers, are the prime candidates for long-term therapy, but the lower risk patients may also receive some benefit.

摘要

β受体阻滞剂汇总项目(BBPP)的目标是收集和分析来自主要长期二级预防试验的数据,以确定心肌梗死后患者中是否存在某些亚组,与普通患者群体相比,他们从β受体阻滞剂治疗中获益程度或多或少有所不同。获得了来自9项试验、涉及13679名患者的1年全因死亡率数据。总体而言,与安慰剂组相比,β受体阻滞剂组的死亡率低24%。然而,这些试验的结果存在异质性,这些试验测试了7种不同的β受体阻滞剂。安慰剂组死亡率高的亚组(例如有既往心肌梗死(MI)、心绞痛、机械或电气并发症以及使用洋地黄病史的患者)似乎特别受益于β受体阻滞剂治疗。这些发现在9项试验中是一致的。低风险亚组的患者似乎也从β受体阻滞剂中获益,但从绝对意义上讲,这种获益较小,且在各试验中不一致。没有证据表明治疗结果与性别、心率或血压的基线水平或入院后开始治疗的时间有关。总之,汇总项目表明,无β受体阻滞剂禁忌证的高风险心肌梗死患者是长期治疗的主要候选对象,但低风险患者也可能会有一些获益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验